查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041726

流感診斷測試市場預測至2034年—按測試類型、最終用戶和地區分類的全球分析

Influenza Diagnostic Tests Market Forecasts to 2034 - Global Analysis By Test Type, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球流感診斷測試市場規模將達到 12 億美元，並在預測期內以 5.6% 的複合年成長率成長，到 2034 年將達到 20 億美元。

流感診斷檢測是一種旨在識別出現呼吸道症狀的患者體內是否有流感病毒的醫療程序。諸如恒溫環型核酸擴增(LAMP) 和核酸序列擴增 (NASBA) 等新興技術提供了更快速、更簡單的檢測方法。快速且準確的診斷，即透過擴增和檢測病毒來提供精確結果，對於早期治療和有效的公共衛生措施至關重要。

根據美國疾病管制與預防中心（CDC）的估計，2021-2022流感季美國共發生900萬例流感病例，400萬人次因流感就診，10萬人次因流感住院治療，5000人次因流感死亡。與新冠疫情爆發前的幾個流感季類似，83%的死亡病例為老年人。

意識提升和教育

健康素養計畫旨在教育大眾識別流感症狀、了解疾病的潛在嚴重性以及診斷檢測在有效治療和預防中的重要性。公共衛生宣傳活動、教育舉措和溝通活動有助於意識提升。此外，醫護人員識別和應對流感病例的能力也在不斷提高，這推動了市場擴張。

高成本

流感診斷檢測的高昂費用可能會阻礙醫護人員和患者使用這些檢測，尤其是在醫療資源有限或醫療預算緊張的地區。這可能導致漏診、延誤治療和疾病管理不善。此外，諸如支付給參與檢測的專家的費用以及檢體採集材料等額外成本也會阻礙市場成長。

診斷技術的進步

分子診斷技術，特別是逆轉錄聚合酵素鏈鎖反應（RT-PCR），取得了顯著進展，提高了流感病毒檢測的敏感度和特異性。這些進步使得病毒株的快速準確鑑定成為可能，從而支持醫護人員及時做出決策和進行病患管理。此外，免疫檢測和核酸擴增技術也在不斷發展，透過提供更廣泛的診斷選擇，進一步拓展了市場。

缺乏意識

醫療專業人員可能並未充分了解每項檢測的益處、限制以及結果的正確解讀。這可能導致診斷檢測利用不足或使用不當，進而造成診斷延誤和患者管理不善。此外，許多人可能並未意識到這些檢測的重要性，這導致檢測服務需求下降，錯失早期發現和有效疾病管理的機會，並阻礙市場成長。

新冠疫情的影響

新冠疫情從多個方面對流感診斷檢測市場產生了負面影響。全球醫療系統優先應對新冠肺炎的診斷，導致流感診斷檢測的整體需求下降。新冠肺炎和流感的症狀常常重疊，僅憑臨床症狀難以區分兩者。此外，疫情也影響了醫療支出重點，可能影響對流感診斷技術的投資，進而阻礙市場擴張。

在預測期內，分子診斷檢測領域預計將佔據最大佔有率。

分子診斷檢測領域預計將佔據最大的市場佔有率，因為該領域利用分子生物學技術檢測和識別流感病毒。這些檢測以其高靈敏度和特異性以及區分不同流感亞型的能力而聞名。此外，逆轉錄聚合酵素鏈鎖反應(RT-PCR) 等關鍵技術的應用有助於更全面地了解流行流感病毒的遺傳特徵，從而推動了該領域的成長。

預計在預測期內，研究領域的複合年成長率將最高。

預計在預測期內，研究機構板塊將呈現最高的複合年成長率。這是因為該板塊在流感診斷領域的發展中發揮著至關重要的作用，其進行的研究旨在提高現有檢測方法的敏感度、特異性和效率。該板塊致力於開發新型診斷檢測方法，包括先進的分子技術、就地檢驗設備和血清學檢測。此外，該板塊還為醫療專業人員提供重要數據，並在檢驗新的診斷技術方面發揮關鍵作用，這推動了該板塊的擴展。

市佔率最大的地區：

由於包括PCR等分子檢測在內的先進診斷技術的廣泛應用，亞太地區在預測期內佔據了最大的市場佔有率。這些技術具有更高的靈敏度和特異性。該地區的主要市場包括BioConcept、雅培、Quidel Corporation和賽默飛世爾科技公司。此外，該地區人口密度高且互聯互通程度高，凸顯了有效流感監測和應對的必要性，這也推動了該地區市場的發展。

複合年成長率最高的地區：

北美地區預計將在預測期內保持最高的複合年成長率，這得益於其完善的醫療基礎設施和民眾對感染疾病的高度重視。 RT-PCR等分子診斷檢測方法在流感檢測中具有高靈敏度和高準確性，已被廣泛應用。此外，診斷技術的持續創新，使其能夠應對新的病毒株和全球健康挑戰，也推動了該地區的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球流感診斷檢驗市場：依檢驗類型分類

  • 分子診斷方法
    • 簡化擴增法（SAMBA）
    • RT-PCR
    • 基於核酸序列的擴增檢測（NASBAT）
    • 恒溫環型核酸擴增（LAMP）
    • 其他分子診斷方法
  • 常規診斷測試
    • 病毒培養
    • 快速流感診斷測試（RIDT）
    • 血清學檢測
    • 直接螢光試驗（DFAT）
  • 其他測試類型

第6章：全球流感診斷檢測市場：依最終用戶分類

  • 研究所
  • 醫院
  • 診斷中心
  • 其他最終用戶

第7章 全球流感診斷檢測市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第8章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第9章：公司簡介

  • Becton, Dickinson and Company
  • Coris BioConcept
  • Meridian Bioscience Inc.
  • Abbott
  • Sekisui Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • Thermo Fischer Scientific Inc.
Product Code: SMRC24789

According to Stratistics MRC, the Global Influenza Diagnostic Tests Market is accounted for $1.2 billion in 2026 and is expected to reach $2.0 billion by 2034 growing at a CAGR of 5.6% during the forecast period. Influenza diagnostic tests are medical procedures designed to identify the presence of influenza viruses in individuals experiencing respiratory symptoms. Emerging technologies, such as loop-mediated isothermal amplification (LAMP) and nucleic acid sequence-based amplification (NASBA), offer faster and simpler alternatives. Rapid and accurate diagnosis is crucial for prompt treatment and effective public health measures that amplify and detect viruses, providing accurate results.

According to estimates by the Centers for Disease Control and Prevention, there were 9 million flu cases, 4 million influenza-related medical appointments, 100,000 flu-related hospitalizations, and 5,000 flu-related fatalities during the 2021-2022 seasons in the U.S. Similar to recent seasons preceding the COVID-19 outbreak, 83% of fatalities were caused by older people.

Market Dynamics:

Driver:

Increased awareness and education

Health literacy programs educate individuals on recognizing influenza symptoms, understanding the potential severity of the disease, and appreciating the role of diagnostic tests in effective treatment and prevention. Public health campaigns, educational initiatives, and communication efforts contribute to raising awareness among healthcare professionals and the general public. Furthermore, healthcare providers are better equipped to recognize and respond to influenza cases, which are boosting this market expansion.

Restraint:

High cost

The high costs associated with influenza diagnostic tests can deter healthcare providers and patients from utilizing them, particularly in resource-limited settings or regions with constrained healthcare budgets. This can result in underdiagnosis, delayed treatment, and compromised disease management. In addition, there may be additional expenses related to test administration, such as professional fees and specimen collection supplies, hampering market growth.

Opportunity:

Advancements in diagnostic technologies

Molecular diagnostic technologies, notably reverse transcription-polymerase chain reaction (RT-PCR), have seen remarkable progress, offering heightened sensitivity and specificity in detecting influenza viruses. These advancements enable rapid and accurate identification of viral strains, aiding healthcare professionals in timely decision-making and patient management. Moreover, immunoassays and nucleic acid amplification techniques continue to evolve, contributing to a diverse array of diagnostic options, thereby driving this market size.

Threat:

Lack of awareness

Healthcare providers may not be familiar with the advantages, limitations, and proper interpretation of the results associated with each test. This can lead to underutilization or inappropriate utilization of diagnostic tests, potentially resulting in delayed diagnosis and suboptimal patient management. Moreover, many individuals may not be aware of its importance, which contributes to a lower demand for testing services, leading to missed opportunities for early detection and effective disease control and impeding this market.

Covid-19 Impact

The COVID-19 pandemic has had a negative impact on the influenza diagnostic test market in several ways. Healthcare systems worldwide have prioritized COVID-19 diagnostics, leading to a decrease in the overall demand for influenza diagnostic tests. The symptoms of COVID-19 and influenza often overlap, making it challenging to differentiate between the two based solely on clinical presentations. Further, the pandemic has also influenced healthcare spending priorities, potentially affecting investments in diagnostic technologies for influenza and hindering the market's expansion.

The molecular diagnostic assay segment is expected to be the largest during the forecast period

The molecular diagnostic assay segment is estimated to hold the largest share due to a category of tests that utilize molecular biology techniques to detect and identify influenza viruses. These tests are known for their high sensitivity, specificity, and capacity to distinguish between different influenza subtypes. Moreover, they contribute to a more comprehensive understanding of the genetic characteristics of circulating influenza viruses using prominent methods like reverse transcription-polymerase chain reaction (RT-PCR), boosting this segment's growth.

The research laboratories segment is expected to have the highest CAGR during the forecast period

The research laboratories segment is anticipated to have highest CAGR during the forecast period, due to they play a pivotal role in advancing the field of influenza diagnostics by conducting studies that aim to enhance the sensitivity, specificity, and efficiency of existing tests. They engage in the development of novel diagnostic assays, such as advanced molecular techniques, point-of-care testing devices, and serological assays. Furthermore, Research laboratories also play a key role in validating new diagnostic technologies providing essential data to guide healthcare practitioners propelling this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a growing adoption of advanced diagnostic technologies, including molecular assays like PCR, as they offer higher sensitivity and specificity. This region is home to some of the major key markets, such as BioConcept, Abbott, Quidel Corporation, and Thermo Fisher Scientific Inc. In addition, the region's high population density and interconnectedness emphasize the need for effective influenza surveillance and control measures that drive the market in this region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to a well-established healthcare infrastructure and a high level of awareness regarding infectious diseases. There is a widespread adoption of molecular diagnostic assays such as RT-PCR, which offer high sensitivity and accuracy in influenza detection. Moreover, continuous innovation in diagnostic technologies, ensuring that they align with emerging viral strains and global health challenges, thereby boosts this region's growth.

Key players in the market

Some of the key players in the Influenza Diagnostic Tests Market include Becton, Dickinson and Company , Coris BioConcept, Meridian Bioscience Inc., Abbott, Sekisui Diagnostics, F. Hoffmann-La Roche Ltd, Hologic Inc., DiaSorin SpA, Quidel Corporation and Thermo Fischer Scientific Inc.

Key Developments:

In September 2023, Navigate BioPharma Services, Inc., announced a strategic collaboration with BD (Becton, Dickinson and Company), to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In July 2023, Thermo Fisher Scientific Inc. announced it has entered into a definitive agreement to acquire CorEvitas, LLC ("CorEvitas"), for approved medical treatments and therapies, from Audax Private Equity ("Audax").

In May 2023, Thermo Fisher, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency of Indonesia (BRIN, Badan Riset dan Inovasi Nasional) to enable and enhance the country's national research and innovation infrastructure and capability.

Test Types Covered:

  • Molecular Diagnostic Assay
  • Traditional Diagnostic Test
  • Other Test Types

End Users Covered:

  • Research Laboratories
  • Hospitals
  • Diagnostics Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostic Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Molecular Diagnostic Assay
    • 5.2.1 Simple Amplification-Based Assay (SAMBA)
    • 5.2.2 RT-PCR
    • 5.2.3 Nucleic Acid Sequence-Based Amplification Test (NASBAT)
    • 5.2.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
    • 5.2.5 Other Molecular Diagnostic Assays
  • 5.3 Traditional Diagnostic Test
    • 5.3.1 Viral Culture
    • 5.3.2 Rapid Influenza Diagnostic Test (RIDT)
    • 5.3.3 Serological Assay
    • 5.3.4 Direct Fluorescent Antibody Test (DFAT)
  • 5.4 Other Test Types

6 Global Influenza Diagnostic Tests Market, By End User

  • 6.1 Introduction
  • 6.2 Research Laboratories
  • 6.3 Hospitals
  • 6.4 Diagnostics Centers
  • 6.5 Other End Users

7 Global Influenza Diagnostic Tests Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Becton, Dickinson and Company
  • 9.2 Coris BioConcept
  • 9.3 Meridian Bioscience Inc.
  • 9.4 Abbott
  • 9.5 Sekisui Diagnostics
  • 9.6 F. Hoffmann-La Roche Ltd
  • 9.7 Hologic Inc.
  • 9.8 DiaSorin SpA
  • 9.9 Quidel Corporation
  • 9.10 Thermo Fischer Scientific Inc.

List of Tables

  • Table 1 Global Influenza Diagnostic Tests Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 4 Global Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 5 Global Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 6 Global Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 7 Global Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 8 Global Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 9 Global Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 10 Global Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 11 Global Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 12 Global Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 13 Global Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 14 Global Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 15 Global Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 16 Global Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 17 Global Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 18 Global Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 19 Global Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 20 North America Influenza Diagnostic Tests Market Outlook, By Country (2023-2034) ($MN)
  • Table 21 North America Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 22 North America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 23 North America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 24 North America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 25 North America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 26 North America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 27 North America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 28 North America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 29 North America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 30 North America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 31 North America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 32 North America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 33 North America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 34 North America Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 North America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 36 North America Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 37 North America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 38 North America Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 39 Europe Influenza Diagnostic Tests Market Outlook, By Country (2023-2034) ($MN)
  • Table 40 Europe Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 41 Europe Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 42 Europe Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 43 Europe Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 44 Europe Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 45 Europe Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 46 Europe Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 47 Europe Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 48 Europe Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 49 Europe Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 50 Europe Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 51 Europe Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 52 Europe Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 53 Europe Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 54 Europe Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 55 Europe Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 56 Europe Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 57 Europe Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 58 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Country (2023-2034) ($MN)
  • Table 59 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 60 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 61 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 62 Asia Pacific Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 63 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 64 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 65 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 66 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 67 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 68 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 69 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 70 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 71 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 72 Asia Pacific Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 73 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 74 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 75 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 76 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 77 South America Influenza Diagnostic Tests Market Outlook, By Country (2023-2034) ($MN)
  • Table 78 South America Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 79 South America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 80 South America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 81 South America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 82 South America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 83 South America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 84 South America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 85 South America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 86 South America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 87 South America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 88 South America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 89 South America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 90 South America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 91 South America Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 92 South America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 93 South America Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 94 South America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 95 South America Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 96 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Country (2023-2034) ($MN)
  • Table 97 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 98 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 99 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2023-2034) ($MN)
  • Table 100 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By RT-PCR (2023-2034) ($MN)
  • Table 101 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 102 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2023-2034) ($MN)
  • Table 103 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2023-2034) ($MN)
  • Table 104 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 105 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 106 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 107 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Serological Assay (2023-2034) ($MN)
  • Table 108 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 109 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 110 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By End User (2023-2034) ($MN)
  • Table 111 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2023-2034) ($MN)
  • Table 112 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 113 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2023-2034) ($MN)
  • Table 114 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other End Users (2023-2034) ($MN)